MedTrace Logo

Benefits of Almond Consumption in Modulation of Intestinal Microbiome and Novel Disease Risk Biomarkers

NCT03327441 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2023-03-17

No results posted yet for this study

Summary

The overall goal is to assess the health benefits of almond consumption on gut microbiome patterns and their association with circulating disease risk biomarkers, as well as the processes that control those pathways. Health benefits will be assessed relative to a omelette control.

Conditions

  • Microbiota

Interventions

OTHER

Almonds

Almonds will be provided as 15% energy

OTHER

Omelette

Omelettes will be provided as 15% energy

Sponsors & Collaborators

  • Almond Board of California

    collaborator OTHER

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Rotimi Aluko, PhD · University of Manitoba

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-01
Primary Completion
2019-04-30
Completion
2019-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03327441 on ClinicalTrials.gov